To order this 550+ page report, please visit
this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Key Inclusions
§
A detailed review of the overall landscape of companies
that are engaged in the manufacturing of cell-based therapies, including
information on the type of cells manufactured (including immune cells (including
T cells, dendritic cells, NK cells), stem cells (including adult stem cells,
human embryonic stem cells and induced pluripotent stem cells) and others),
source of cells (autologous and allogeneic), scale of manufacturing, type of
cell cultures (adherent and suspension), purpose of production (fulfilling
in-house requirements and contract services), manufacturing capabilities /
services offered (including R&D, cell culture development, quality testing,
packaging, labelling, cell banking, cryopreservation, fill / finish services,
and regulatory affairs management), location of headquarters and location of
their respective manufacturing facilities.
§
An analysis of the various expansion initiatives undertaken
by service providers, in order to augment their respective cell therapy
manufacturing capabilities, over the period 2015-2019 (till October), taking into
consideration parameters, such as year of expansion, type of cells, scale of
operation, purpose of expansion (facility expansion and new facility), location
of manufacturing facility, and most active players (in terms of number of
expansion initiatives undertaken).
§
An analysis of the recent partnerships focused on the
manufacturing of cell-based therapies, which have been established in the
period 2014-2019 (till November), based on various relevant parameters, such as
the year of agreement, type of partnership, type of cells, and scale of
operation (preclinical, clinical and commercial).
§
Informed estimates of the annual commercial and clinical
demand for cell therapies (in terms of number of cells produced and area
dedicated to manufacturing), which were further analyzed based on type of
cells.
§
An estimate of the overall, installed capacity for
manufacturing cell-based therapies based on information reported by industry
stakeholders in the public domain, highlighting the distribution of the
available capacity on the basis of scale of operation (clinical and
commercial), size of the organization (small, mid-sized and large firms) and
key geographical regions (North America, EU and Asia Pacific).
§
An in-depth analysis of cell therapy manufacturers using three
versatile representations, namely [A] a three dimensional grid analysis,
presenting the distribution of companies on the basis of type of cells manufactured,
scale of operation and purpose of production, [B] a logo landscape based on the
type of cells manufactured, geographical location of manufacturer (North
America, Europe and Asia Pacific) and type and size of organization
(non-industry players, and small, mid-sized and large companies), and [C] a
schematic world map representation, highlighting the geographical locations of
cell therapy manufacturing facilities of both industry and non-industry
stakeholders.
§
A detailed analysis of the various factors that are likely
to influence the pricing of cell-based therapies, featuring different models /
approaches that may be adopted by manufacturers while deciding the prices of
their proprietary offerings.
§
An elaborate discussion on the role of automation technologies
in improving current manufacturing methods, along with a comparative
(qualitive) analysis of cost differences between manual and automated
processes.
§
A qualitative analysis, highlighting the various factors
that need to be taken into consideration by cell therapy developers while
deciding whether to manufacture their respective products in-house or engage
the services of a CMO.
§
A discussion on cell therapy manufacturing regulations
across various geographies, including the North America (focusing on the US),
Europe and Asia (focusing on Japan), featuring an analysis of the diverse
certifications / accreditations awarded to manufacturing facilities by
important regulatory bodies across the globe.
§
Elaborate profiles of key players (industry and non-industry)
that offer contract manufacturing services for cell-based therapies; each
profile includes an overview of the company / organization, information on its
manufacturing facilities, service portfolio details, recent partnerships and an
informed future outlook.
§
A discussion on affiliated trends, key drivers and
challenges, which are likely to impact the industry’s evolution, under a
comprehensive SWOT framework, which includes a Harvey ball analysis,
highlighting the relative effect of each SWOT parameter on the overall market
dynamics.
§
Insights generated in a market-wide survey, featuring
inputs solicited from experts who are directly and indirectly involved in the
development and / or manufacturing of cell-based therapies.
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/285/request-sample.html
Key
Questions Answered
§
What is the global demand for cell-based therapies?
§
Who are the key manufacturers (industry / non-industry) of
cell-based therapies, across the world?
§
What are the major recent developments (such as
partnerships and expansions) in this industry?
§
What kind of partnership models are commonly adopted by
stakeholders in this domain?
§
What is the current, installed contract manufacturing
capacity for cell therapies?
§
What are the key factors influencing the make
(manufacture in-house) versus buy (outsource) decision related to cell
therapies?
§
What are the key parameters governing the cost of cell
therapy manufacturing?
§
What are important technology platforms (available / under
development) for cell therapy development and manufacturing?
§ What
are the key drivers and growth constraints in cell therapy manufacturing market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be interested in the following titles:
1.
Cell and Advanced
Therapies Supply Chain Management Market, 2019-2030
2.
RNAi Therapeutics
Market (2nd Edition), 2019 – 2030
3.
Gene Therapy Market
(3rd Edition), 2019 – 2030
4.
Stem Cell Therapy
Contract Manufacturing Market, 2019-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
